Screener
Avalo Therapeutics AVTX Business Segments — Salaries, benefits and related costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Clinical expenses | 3,712 | 7,215 | 9,344 | 11,065 |
| CMC expenses | 5,068 | 3,266 | 9,194 | 5,245 |
| License and milestone expenses | 10,000 | — | 10,000 | — |
| Internal expenses: | ||||
| Salaries, benefits and related costs | 2,630 | 2,181 | 5,216 | 4,030 |
| Stock-based compensation expense | 1,680 | 1,116 | 2,923 | 2,418 |
| Other | 79 | 117 | 149 | 175 |
| $23,418 | $14,074 | $37,466 | $23,195 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's business segments — salaries, benefits and related costs?
- Avalo Therapeutics (AVTX) reported business segments — salaries, benefits and related costs of $2.63M in Q2 2026.
- How has Avalo Therapeutics's business segments — salaries, benefits and related costs changed year-over-year?
- Avalo Therapeutics's business segments — salaries, benefits and related costs increased by 20.6% year-over-year, from $2.18M to $2.63M.
- What is the long-term trend for Avalo Therapeutics's business segments — salaries, benefits and related costs?
- Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — salaries, benefits and related costs has grown at a 54.2% compound annual growth rate (CAGR), from $3.58M to $8.5M.
- What does business segments — salaries, benefits and related costs mean?
- Reflects the total personnel-related expenditures, including wages, benefits, and payroll taxes for staff dedicated to the reportable segment. This metric serves as a proxy for the human capital investment required to support the company's research and development operations. Tracking these costs provides insight into the company's organizational growth and operational overhead.
Ask your AI about Avalo Therapeutics's business segments — salaries, benefits and related costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude